Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
Tam
Ying K
YK
Inex Pharmaceutical Corporation, Burnaby, British Columbia, Canada, V5J 5J8. ytam@inexpharm.com
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology; D018899:CpG Islands / Q000276:immunology; D004247:DNA / Q000276:immunology; D006801:Humans; D007114:Immunization / Q000379:methods*; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009838:Oligodeoxyribonucleotides / Q000276:immunology / Q000627:therapeutic use; D009841:Oligonucleotides / Q000276:immunology* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D009838:Oligodeoxyribonucleotides; D009841:Oligonucleotides; D004247:DNA